We welcome you to the EUGENMED website. The project is run by Charité, Universitaetsmedizin Berlin; University Maastricht, and the European Institute of women’s health. It was launched on October 1st 2013 and is funded by the European Commission.
Charité, Universitaetsmedizin Berlin
European Institute of Women’s Health
We will produce an innovative roadmap for implementation of Sex and Gender (S&G) in biomedicine and health research. This will improve the treatment of major chronic diseases such as infarction, heart failure, diabetes, rheumatic disease, etc. in women and men and research in these areas.
We will develop the roadmap in 6 meetings with key stakeholders in European Gender Medicine and Gender Research in the biomedical field. We will design recommendations, guidelines and teaching materials for the implementation of Sex & Gender research for target audiences, doctors, medical associations, teachers, students, researchers, industry, health policy makers, funding agencies and politicians.
Research addressing S&G in biomedical sciences and health care research is emerging as a novel and highly promising field. Interaction of S&G related mechanisms leads to different manifestation of frequent diseases such as infarction, heart failure, diabetes, rheumatic disease, etc. in women and men.
Research in this area will lead to novel, better targeted and therefore more efficient treatment strategies than the previous global approaches and will increase prevention and healthy life expectancy. We will produce an innovative roadmap for implementation of S&G in biomedicine and health research. To achieve these objectives we will develop EUGENMED into an open European Gender Health Network that includes all stakeholders and decision makers.
We will organize 6 meetings with key stakeholders that will result in recommendations, guidelines and teaching materials for the implementation of S&G research for target audiences, doctors, medical associations, teachers, students, researchers, industry, health policy makers, funding agencies and politicians. Materials will be disseminated through a European Gender Health Portal. The aim is to create a truly multi- sectorial sourcing of knowledge, a key factor for building consensus and helping close the participatory governance gaps.
Inclusiveness, openness and transparency will be key principles. Dissemination of S&G strategies to the next generation of medical interventions and therapies will help to improve the health of European citizens. Project outcomes will be fed into relevant policy processes at the EU level e.g. Horizon 20/20. EUGENMED will lead to significant innovations by introducing S&G into research and medical practice and improve European citizens’ health and Europe’s standing in biomedicine.
EUGENMED will identify focal areas of work where sex and gender play a major role and will set timelines for the generation of materials for specific target audiences by the consortium and experts. All materials together will constitute the Roadmap. All partners will contribute to the dissemination of the Roadmap.
WS 1, leader Charité (P1): Sex and gender in clinical medicine and clinical pharmacology.
WS 2, leader Maastricht (P2): Sex and gender in public health and prevention.
WS 3, leader Charité (P1): Sex differences in basic biomedical research and preclinical drug development
WS 4, leader EIWH (P3): Medicines Regulation (WS1) and Medical Education (WS2)
|M.1||Invitation of stake¬holders for Kick-off meeting|
|M.2||EUGENMED gender health portal|
|M.3||Work plan for generation of road map|
|M.4||Targeted materials generated|
|M.5||Bylaws and board of EGMN agreed|
|M.7||Roadmap communicated to decision leaders|
If you are interested in the project, please contact us!